Our securities attorneys are investigating claims on behalf of investors of BioScrip, Inc. (NASDAQ: BIOS) regarding possible violations of federal securities laws following the company’s announcement that it has begun an internal accounting review after identifying internal control deficiencies.

BioScrip, Inc. Stock Losses?

If you acquired shares of BioScrip and would like to speak privately with a securities attorney about your legal rights, call or send us a message.

  • This field is for validation purposes and should be left unchanged.

1-800-254-9493

Stock Drops 15% Amid News of “Internal Control Deficiencies” and “Material Weakness”

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions.

On March 8, 2018, the company released its preliminary fourth quarter and full year financial results for 2017, and announced that it had begun an internal accounting review because it “identified internal control deficiencies in connection with account reconciliations for certain asset and liability accounts,” and that this may cause a delay in the filing of its Form 10-K.

BioScrip also announced that it has separately “identified and will report a material weakness related to certain spreadsheets used to calculate periodic adjustments to accounts.”

Following this news, the share price of BioScrip plummeted more than 15% on high volume to close at $2.59 on March 8, 2018.

Girard Gibbs' Financial Fraud Experience

Girard Gibbs’ financial fraud and securities lawyers have more than two decades of experience prosecuting fraud. Our attorneys have successfully litigated against some of the largest companies in the United States, and we have recovered more than a billion dollars on our clients’ behalf.

We have fought some of the most complex cases brought under federal and state laws nationwide, and our attorneys have been recognized with numerous awards and honors for their accomplishments, including Top 100 Super Lawyers in Northern California, Top Plaintiff Lawyers in California, The Best Lawyers in America, and rated AV Preeminent (among the highest class of attorneys for professional ethics and legal skills).

Noteworthy Financial Fraud Cases

American Express Financial Advisors Securities Litigation $100 million cash settlement for clients alleging American Express steered them into under-performing “shelf space funds” to reap kickbacks
Chase Bank “Check Loan” Litigation $100 million settlement for consumers alleging Chase offered long-term fixed-rate loans, only to later more-than-double required payments
Peregrine Financial Group Customer Litigation Settlements worth $75 million for futures and commodities investors who lost millions in the collapse of Peregrine Financial Group, Inc.
NantHealth Court-appointed Co-Lead Counsel in a securities class action alleging the company’s founder violated federal securities law and artificially inflated stock prices

Our Team

Eric Gibbs

Eric has served in leadership positions in a number of high profile, complex financial lawsuits. He has been recognized as a Daily Journal, among the Top 100 Super Lawyers in Northern California, and a Law360 MVP for Consumer Protection.

David Stein

David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.

Michael Schrag

Michael has over 20 years of experience representing individuals in complex cases involving banking credit card and other financial frauds.